Polygenic modulation of lipoprotein(a)-associated cardiovascular risk.

- 3 Brief title: Lipoprotein(a)-associated cardiovascular risk.
- 4

- 5 <u>Mark Trinder^{a,b}</u>, MSc, Liam R. Brunham^{a,b,c,d}, MD, PhD.
- 6
- ⁷ ^a Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.
- 8 ^b Experimental Medicine Program, University of British Columbia, Vancouver, British
- 9 Columbia, Canada
- 10 ^c Department of Medicine, University of British Columbia, Vancouver, British Columbia,
- 11 Canada
- ¹² ^d Department of Medical Genetics, University of British Columbia, Vancouver, British
- 13 Columbia, Canada
- 14
- 15 **Funding:** This project was supported by the Providence Health Care Research Institute. M.T. is
- 16 supported by a Vanier Canada Graduate Scholarship. L.R.B. is supported by a Michael Smith
- 17 Foundation for Health Research Scholar Award and is a Canada Research Chair in Precision
- 18 Cardiovascular Disease Prevention.
- 19
- 20 **Disclosures:** None.
- 21
- 22 * Address for correspondence:
- 23 Dr. Liam R. Brunham
- 24 Centre for Heart Lung Innovation
- 25 Room 166-1081 Burrard Street
- 26 Vancouver, BC V6Z 1Y6
- 27 Phone: (604) 682-2344 x63929
- 28 Fax: (604) 806-9274
- 29 Email: <u>liam.brunham@ubc.ca</u>
- 30 Twitter handle: @LiamBrunham

31 ABSTRACT

32 Aims: Elevated levels of lipoprotein(a) are one of the strongest inherited risk factors for

33 coronary artery disease (CAD). However, there is variability in cardiovascular risk among

34 individuals with elevated lipoprotein(a). The sources of this variability are incompletely

35 understood. We assessed the effects of a genomic risk score (GRS) for CAD on risk of

36 myocardial infarction among individuals with elevated lipoprotein(a).

37 Methods: We calculated CAD GRSs for 408,896 individuals of British white ancestry from

38 the UK Biobank using 6.27 million common genetic variants. Lipoprotein(a) levels were

39 measured in 310,020 individuals. The prevalence and risk of myocardial infarction versus

40 CAD GRS percentiles were compared for individuals with and without elevated lipoprotein(a)

41 defined as ≥ 120 or 168 nmol/L (≈ 50 or 70 mg/dL, respectively).

42 **Results:** Individuals with elevated lipoprotein(a) displayed significantly greater CAD GRSs

43 than individuals without elevated lipoprotein(a), which was largely dependent on the

44 influence of genetic variants within or near the LPA gene. Continuous levels of CAD GRS

45 percentile were significantly associated with risk of myocardial infarction for individuals with

46 elevated lipoprotein(a). Notably, the risk of myocardial infarction for males with elevated

47 lipoprotein(a) levels, but a CAD GRS percentile in the lower quintile (<20th percentile), was less

48 than the overall risk of myocardial infarction for males with non-elevated lipoprotein(a) levels

49 (hazard ratio [95% CI]: 0.79 [0.64-0.97], p=0.02). Similar results were observed for females.

50 **Conclusion:** These data suggest that CAD genomic scores influence cardiovascular risk among

51 individuals with elevated lipoprotein(a) and may aid in identifying candidates for preventive

52 therapies.

- 53 Keywords: Lp(a), genomic risk score, myocardial infarction, genetic risk, atherosclerosis,
- 54 polygenic

55 INTRODUCTION

56 Lipoprotein(a) is a plasma lipoprotein composed of a low-density lipoprotein particle that 57 is covalently linked to apolipoprotein(a) by a disulfide bond. Lipoprotein(a) levels are among the 58 strongest inherited risk factors for cardiovascular disease^{1–9}, and Mendelian randomization 59 studies suggest that elevated levels of lipoprotein(a) are causal for aortic stenosis¹⁰, heart failure¹¹, ischemic stroke¹², and coronary artery disease (CAD)^{1,13}. Plasma levels of 60 61 lipoprotein(a) are largely determined by genetic factors which include single-nucleotide variants 62 and copy number variants in the kringle IV type 2 (KIV-2) domain of the LPA gene^{5,6,14,15}. 63 Elevated lipoprotein(a) is a common condition that is estimated to affect 1 in 5 64 individuals of European ancestry (plasma lipoprotein(a) levels greater than $50 \text{ mg/dL})^{16}$. 65 Although elevated lipoprotein(a) is associated with increased cardiovascular risk, the optimal 66 treatment of elevated lipoprotein(a) is uncertain. While there are currently no approved therapies for lowering lipoprotein(a), antisense oligonucleotides that target apolipoprotein(a) and reduce 67 lipoprotein(a) levels by up to 80% have been developed and are currently being studied in 68 69 clinical trials^{17–19}. At the individual level, there is substantial variability in cardiovascular risk 70 among individuals with elevated lipoprotein(a)^{1,20,21}, and it remains unclear whether isolated 71 elevated lipoprotein(a) in the absence of other cardiovascular risk factors merits treatment to 72 reduce cardiovascular risk. 73 Recent work suggests that genomic risk scores (GRSs), which summarize the association

of millions of common genetic variants with risk of CAD into a single value, may be a useful
tool for improving risk prediction of CAD^{7,22–25}. Here we tested the hypothesis that, among
individuals with elevated lipoprotein(a), the risk of CAD would be modulated by a GRS for
CAD, and that this may be useful for risk stratification.

78

79 METHODS

80 Study population.

81 We studied participants from the UK Biobank, a large population-based prospective 82 cohort study from the United Kingdom that aims to improve the prevention, diagnosis and 83 treatment of disease by following the health and well-being of approximately 500 000 84 individuals. Individuals were enrolled between 2006-2010 and were between 40-69 years-of-age. 85 Individuals underwent deep phenotyping at study enrollment and DNA was collecting for genotyping, as previously described²⁶. The UK Biobank resource was approved by the UK 86 87 Biobank Research Ethics Committee, and all participants provided written informed consent to 88 participate in the study. This study was approved by the UK Biobank (application ID: 42857) 89 and by the Clinical Research Ethics Board of the University of British Columbia (H18-02181). 90 **Biochemical measurements.** 91 Biochemical measurements were assessed at the time of study enrollment (Supplemental 92 Methods; Supplemental Table 1). Lipoprotein(a) was measured using an immuno-turbidimetric 93 method on the Beckman Coulter AU5800 platform (Randox Bioscience, UK), which is 94 essentially isoform insensitive²⁷. Where indicated, lipoprotein(a) concentration was converted 95 from nmol/L to mg/dL by dividing values by $2.4^{3,28}$. Elevated lipoprotein(a) was defined as lipoprotein(a) levels $\geq 120 \text{ nmol/L}$ ($\approx 50 \text{ mg/dL}$) or $\geq 168 \text{ nmol/L}$ ($\approx 70 \text{ mg/dL}$)^{27,29,30}. For 96 97 individuals taking cholesterol-lowering medication, total cholesterol and low-density lipoprotein 98 cholesterol levels were adjusted by multiplying on-treatment lipid levels by 1.43, corresponding 99 to an estimated 30% reduction in low-density lipoprotein cholesterol^{31,32}. 100 Calculation of coronary artery disease genomic risk scores.

101	The weightings used to calculate CAD GRSs were obtained from the Cardiovascular
102	Disease Initiative Knowledge Portal and can be accessed at <u>www.broadcvdi.org</u> ^{7,22} . CAD GRSs
103	were calculated for individuals of British white ancestry using imputed genetic data that were not
104	flagged as outliers for excess missingness or heterozygosity ²⁶ . CAD GRSs were calculated using
105	6.27 million of the 6.63 million potential single-nucleotide variants described by Khera et al.
106	(2018). Variants that displayed deviation from Hardy-Weinberg equilibrium ($p<1x10^{-6}$), a
107	genotyping rate <95%, or minor allele frequency <1% were removed. The PLINK score function
108	was used to multiply the number of alleles associated with adjusted β -coefficient for increased
109	risk of CAD at each single-nucleotide variant by its respective linkage disequilibrium-adjusted
110	weight and sums these products across all available variants to generate a GRS for each
111	individual ^{23,33} . CAD GRSs were also calculated after excluding genetic variants located within
112	7.5 million base pairs upstream and downstream of the LPA gene. CAD GRSs were converted
113	into percentiles relative to the distribution of CAD GRSs in the UK Biobank study population.
114	The top 100 genetic variants used in the calculation of CAD GRSs were manually curated
115	for association with known cardiovascular risk factors using the NHGRI-EBI Genome-Wide
116	Association Study Catalog ³⁴ .

117 Definition of cardiovascular events.

Phenotypes, including the primary outcome of myocardial infarction, were defined using reports from medical history interviews occurring at enrollment, International Classification of Diseases (ICD)-9th and -10th Revision codes, and death registry records (Supplemental Methods, Supplemental Table 2). Events occurring before and after enrolment were included unless otherwise stated. Events occurring prior to enrolment were identified by either self-reported medical history and/or previous hospital admission within an electronic health record. Incident

124 events were defined by hospital admission with an electronic health record entry or death 125 records. Events were censored on the date of loss-to-follow-up or if individuals remained event-126 free up to March 31, 2017. 127 Statistical analyses. 128 All statistical analyses were performed using R version 3.6.0 software (R Core Team, 129 2019). Individuals with missing values were excluded from analyses. 130 Chi-square tests were used for contingency analyses. For comparison of 2 groups, data 131 were analyzed with an unpaired t-test or Mann–Whitney U test as appropriate. For comparison 132 of more than 2 groups, data were analyzed with one-way analysis of variance test (with Tukey's multiple comparison post hoc tests) or Kruskal-Wallis test, as appropriate (with Dunn's multiple 133 134 comparison post hoc tests). 135 The distributions of CAD GRS percentiles were compared between individuals with 136 traditional cardiovascular risk factors determined at study enrollment that included: 137 hypertension, severe hypercholesterolemia (low-density lipoprotein cholesterol levels \geq 4.9 138 mmol/L), diabetes mellitus, obesity (body mass index \geq 30 kg/m²), current smoker status, 139 insufficient physical activity (classification of low activity level according to the International 140 Physical Activity Questionnaire), insufficient fruit and vegetable intake (< 3 servings per day; 141 sum of cooked vegetable intake, fresh fruit intake, and salad/raw vegetable intake), and strata of 142 lipoprotein(a) levels (<72, 72-120, 120-168, and \geq 168 nmol/L). The prevalence of cardiovascular events of interest were calculated for each decile of 143 144 CAD GRS percentile. Linear regression models were used to assess the correlation between cardiovascular disease prevalence and CAD GRS percentile using elevated lipoprotein(a) status 145 146 as a covariate or interactive term

147	Time-to-event analyses were analyzed with the "survival" version 2.43-3 package for R		
148	with Log-rank tests. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated		
149	using Cox regression models stratified by sex with age of event as a time scale. All Cox		
150	regression models were adjusted for the first 4 principal components of ancestry and genotyping		
151	array.		
152	Statistical significance was claimed when two-sided p-values were <0.05.		
153			
154	RESULTS		
155	Characteristics of individuals from the UK Biobank.		
156	This study included 408,896 individuals of British white ancestry from the UK Biobank		
157	study, of whom 310,020 had lipoprotein(a) levels measured at enrollment (Table 1). The average		
158	age of enrollment was 56.9 years-of-age (standard deviation: 8.0 years) and 54.1% were female.		
159	Genomic risk scores for coronary artery disease associate with the prevalence of traditional		
160	cardiovascular risk factors.		
161	First, we assessed how CAD GRSs were associated with traditional cardiovascular risk		
162	factors. Individuals with hypertension, severe hypercholesterolemia, diabetes mellitus, obesity,		
163	and a current smoker status displayed significantly higher CAD GRS percentiles than those		
164	without the cardiovascular risk factor of interest (Mann-Whitney U test: p=0.0006 for smoking		
165	status, p<0.0001 for others; Figure 1a-e; Supplemental Table 3). There was also a significant		
166	stepwise increase in the median CAD GRS percentile as the number of traditional CAD risk		
167	factors per an individual increased (Kruskal-Wallis test: p<0.0001; Figure 1f). Alternatively,		
168	CAD GRSs did not display an association with insufficient physical activity (Mann-Whitney U		

169 test: p=0.40) or an insufficient daily intake of fruits and vegetables (Mann–Whitney U test:

170 p=0.40) (Supplemental Figure 1).

171 Individuals with elevated lipoprotein(a) have higher genomic risk scores for coronary artery 172 disease.

173 CAD GRS percentiles displayed a significant and strong association with lipoprotein(a) 174 levels (Kruskal–Wallis test: p<0.0001; Figure 2A). Notably, individuals with lipoprotein(a) 175 levels greater or equal to 120 nmol/L (\approx 50 mg/dL) displayed a median CAD GRS of 65.2 176 percentile. Individuals with elevated lipoprotein(a) tended to have CAD GRSs that were 177 comparable to individuals with multiple traditional cardiovascular risk factors at the time of 178 study enrollment (i.e. the median CAD GRS percentile for individuals with hypertension, severe 179 hypercholesterolemia, diabetes mellitus, obesity, and current smoker status was 65.5 percentile). 180 The higher CAD GRS percentile observed among individuals with elevated lipoprotein(a) was 181 dependent on genetic loci within and around the LPA gene. When CAD GRSs were re-calculated 182 after the exclusion of DNA variants located 7.5 million base pairs up- or downstream of the LPA

183 gene, the difference in CAD GRSs across strata of lipoprotein(a) levels was attenuated (Kruskal-

184 Wallis test: p=0.02; Figure 2B; Supplemental Table 4).

185 The strong association between CAD GRSs and elevated lipoprotein(a) reflects both the

186 high heritability and atherogenicity of lipoprotein(a) particles. Specifically, the locus in the CAD

187 GRS with the greatest standardized effect size (rs186696265; GRCh37 position

188 6:161111700:C:T), and hence the greatest influence on CAD GRSs by weight, is known to

189 associate with lipoprotein(a) levels (Figure 2C). Moreover, 6 of the top 100 loci with the largest

190 standardized effect sizes in the CAD GRSs have known associations with lipoprotein(a) levels

191 and include: rs186696265, rs10455872 (6:161010118:A:G). rs55730499 (6:161005610:C:T),

192 rs118039278 (6:160985526:G:A), rs56393506 (6:161089307:C:T), and rs4252185

193 (6:161123451:T:C) (Figure 2C).

194 Association of lipoprotein(a) levels with risk of myocardial infarction.

Consistent with previous studies^{1,27}, lipoprotein(a) levels were right-skewed among individuals of British white ancestry from the UK Biobank (Figure 3A). The median and interquartile range of lipoprotein(a) levels was 20.1 and 50.9 nmol/L, respectively. The risk of myocardial infarction was significantly associated with lipoprotein(a) levels for both male (adjusted HR [95% CI] 1.06 [1.06-1.07] per 20 nmol/L increase, p<0.0001; Figure 3B) and female UK Biobank participants (adjusted HR [95% CI] 1.03 [1.02-1.05] per 20 nmol/L

201 increase, p<0.0001; Figure 3C).

202 Risk of myocardial infarction is modulated by coronary artery disease genomic risk score 203 among individuals with elevated lipoprotein(a).

204 Next, we assessed if CAD GRSs may help explain some of the heterogeneity in risk of 205 CAD that is observed in individuals with elevated lipoprotein(a), defined as ≥ 120 nmol/L (≈ 50 206 mg/dL). The prevalence of myocardial infarction was significantly associated with deciles of 207 CAD GRS percentile in both individuals with and without elevated lipoprotein(a) (Figure 4A). 208 Individuals with elevated lipoprotein(a) displayed a significantly greater prevalence of 209 myocardial infarction relative to individuals with non-elevated lipoprotein(a) levels across all 210 deciles of CAD GRS (β [SE] = 0.786 [0.194], R²=0.913, p=0.0009; Figure 4A; Supplemental 211 Table 5). This effect was even more striking when deciles of CAD GRS percentile were 212 calculated after excluding loci associated within and in proximity to the LPA gene (β [SE] = 213 1.494 [0.216], R²=0.920, p<0.0001; Figure 4B). Individuals with elevated lipoprotein(a) but a 214 CAD GRS in the first decile had a lower prevalence of myocardial than individuals with non-

215 elevated lipoprotein(a) and a CAD GRS in the tenth decile (2.98% vs 6.61%, Figure 4B). These 216 data indicate that the CAD GRS modulates the risk of myocardial infarction associated with 217 elevated lipoprotein(a). There was no significant interaction between lipoprotein(a) status and 218 CAD GRS that included or excluded loci in and nearby LPA. 219 We next examined the cumulative risk of myocardial infarction across time in males and 220 females with elevated lipoprotein(a) as a function of CAD GRS. We observed a significant effect 221 of the CAD GRS on risk of myocardial infarction in these individuals with elevated 222 lipoprotein(a). The adjusted HR for males was 1.28 (95% CI: 1.23-1.33, p<0.0001) and for 223 females was 1.16 (95% CI: 1.08-1.25, p<0.0001) per 20 unit increase in continuous CAD GRS 224 percentile. Notably, the risk of myocardial infarction for individuals with elevated lipoprotein(a) 225 levels, but a CAD GRS percentile in the lower quintile (<20th percentile), was less than or 226 equivalent to the overall risk of myocardial infarction for those with non-elevated lipoprotein(a) 227 levels (adjusted HR [95% CI]: 0.79 [0.64-0.97] and 0.91 [0.66-1.26] with p=0.02 and p=0.58 for males and females, respectively; Figure 4C). Similar results were observed when the risk of 228 229 myocardial infarction was compared between quintiles of CAD GRS percentiles that excluded 230 loci surrounding the LPA gene (adjusted HR [95% CI] were 0.85 [0.73-0.98] and 0.83 [0.64 -231 1.07] with p=0.03 and p=0.15 for males and females, respectively; Figure 3D). 232 Even among individuals with higher lipoprotein(a) levels of $\geq 168 \text{ nmol/L}$ ($\approx 70 \text{ mg/dL}$ 233 and comprising the top 3.5 percent of the population distribution), we observed a significant 234 effect of the CAD GRS percentiles on risk of myocardial infarction (Supplemental Figure 2). 235 Specifically, among these individuals, the adjusted HR for myocardial infarction was 1.31 for 236 males (95% CI: 1.22-1.41, p<0.0001) and 1.19 for females (95% CI: 1.04-1.34, p=0.009) per 20 237 percentile increase in continuous CAD GRS. These findings highlight that genomic background

238	can still modulate the risk of myocardial infarction for individuals with elevated lipoprotein(a)		
239	and suggest that the CAD GRS may be useful to stratify cardiovascular risk in individuals		
240	identified to have elevated lipoprotein(a).		
241	Effect of coronary artery disease genomic risk score on other cardiovascular outcomes		
242	associated with lipoprotein(a).		
243	Lipoprotein(a) is also likely a causal risk factor for peripheral vascular disease and aortic		
244	stenosis ^{10,35} , and, to a lesser extent, ischemic stroke ^{12,36} . Since there is considerable overlap of		
245	risk factors between these cardiovascular conditions and CAD ³⁷ , we sought to assess if CAD		
246	GRSs also modulate the risk of these conditions among individuals with elevated lipoprotein(a).		
247	We observed a trend towards increased prevalence of peripheral vascular disease (β [SE]: 0.120		
248	$[0.055]$, p=0.002, R ² =0.712), aortic stenosis (β [SE]: 0.241 [0.056], p=0.0005, R ² =0.615), and		
249	ischemic stroke (β [SE]: 0.182 [0.072], p=0.02, R ² =0.361) for individuals with elevated		
250	lipoprotein(a), relative to individuals with non-elevated lipoprotein(a) (Supplemental Figure 3;		
251	Supplemental Tables 6-8). The strength of the association between prevalence of ischemic stroke		
252	and deciles of CAD GRS percentile was weak due to fewer events relative to the other		
253	cardiovascular conditions.		

254

255 **DISUCSSION**

Here we report that common genetic factors modify the risk of myocardial infarction and other adverse cardiovascular outcomes among individuals with elevated lipoprotein(a). These data highlight the atherogenicity and high heritably of lipoprotein(a) levels, as reflected by the substantial increases in CAD GRSs observed among individuals with elevated lipoprotein(a). The increased CAD GRSs observed in individuals with elevated lipoprotein(a) were almost

261 entirely explained by single-nucleotide variants near the *LPA* gene having large weighted effect
262 sizes, and thus, a large influence on the CAD GRS.

263 This work adds to the growing literature highlighting the role that polygenic factors play 264 in modifying the penetrance or expressivity of monogenic conditions, such as familial 265 hypercholesterolemia^{22,38–40}. To our knowledge, this is the first study to describe the polygenic 266 modulation of myocardial infarction and other adverse cardiovascular outcomes by CAD GRSs 267 among individuals with elevated lipoprotein(a).

268 Elevated lipoprotein(a) is a common monogenic condition resulting from genetic 269 variation in and around the LPA gene, which includes single-nucleotide variants and copy 270 number variation in the KIV-2 DNA sequence. Variation in the number of KIV-2 repeats results 271 in plasma lipoprotein(a) particles that display considerable interindividual variation in 272 apolipoprotein(a) isoform size (ranging from 300-800 kDa). The number of KIV-2 repeats are 273 also inversely associated with lipoprotein(a) levels. However, lipoprotein(a) levels (*i.e.* molar 274 concentration), rather than apo(a) isoform size, appears to be most strongly associated with risk 275 of CAD^{20,41,42}.

276 Approximately 1 in 5 individuals of European ancestry have lipoprotein(a) levels greater 277 than 120 nmol/L (\approx 50 mg/mL), which is a common cut-off for estimation of cardiovascular risk 278 and consideration of therapy³⁰. Lipoprotein(a) levels greater than 120 nmol/L are also common 279 among individuals of African (1 in 4), South and South East Asian (~1 in 10), Arab (~1 in 10), 280 and Latin American (~1 in 7) ethnicity and also associated with risk of CAD in these 281 populations^{20,43,44}. However, the optimal management of patients with elevated lipoprotein(a) is 282 uncertain. Antisense inhibitors that potently lower lipoprotein(a) are currently being studied in 283 clinical trials in subjects with elevated lipoprotein(a) and established cardiovascular disease^{17–19}.

284 Our study suggests that the CAD GRS may be useful for identifying high risk patients that are 285 likely to benefit most from lipoprotein(a)-lowering therapy, or other therapies that reduce 286 cardiovascular risk among individuals with elevated lipoprotein(a). In support of this hypothesis, 287 previous studies have shown that individuals with high genetic risk for CAD demonstrate greater 288 absolute risk reduction of cardiovascular events from statins^{24,45} or PCSK9 inhibitors⁴⁶ relative to 289 individuals at lower genetic risk. In addition, the data presented here suggest that a GRS may be 290 useful to de-risk patients with isolated elevated lipoprotein(a), as we observed that a low GRS in 291 such individuals was associated with a risk of myocardial infarction that was similar to, or lower 292 than, that of individuals with non-elevated lipoprotein(a) and a median GRS. The extent to which 293 CAD GRSs can improve risk prediction beyond established clinical risk scores requires further 294 investigation⁴⁷. However, a major advantage of assessing germline genetic variation for 295 cardiovascular risk assessment is that it only needs to be measured once and can be measured 296 early in life, allowing for earlier intervention before other clinical risk factors may emerge^{7,25,46}. 297 This study has some notable strengths and limitations worthy of consideration. Firstly, we 298 were able to use a very large population of more than 300,000 individuals with standardized 299 lipoprotein(a) measurements using an isoform insensitive assay, and genome-wide genotype 300 data. As such, this represents one of the largest population-based studies of lipoprotein(a) to date. 301 Limitations are that the population studied was comprised of individuals of European ancestry 302 and may not be representative of other global populations. While this aspect of the study reduces 303 the risk of bias or confounding due to population stratification, it also limits the generalization of 304 these results to other ancestral populations. Future studies using large populations of individuals 305 from diverse ancestral backgrounds are therefore essential. Indeed, as the calculation and calibration of the CAD GRSs depend on linkage disequilibrium^{7,23}, which varies substantially 306

307 across ancestries, future studies will be needed to derive and validate CAD GRSs in other 308 ancestral groups. The UK Biobank population also displays a healthy volunteer selection bias 309 relative to the overall health and well-being of individuals living across the United Kingdom⁴⁸. 310 Furthermore, the CAD GRS was constructed to best identify individuals at risk of CAD and is 311 likely not as sensitive at identifying individuals at risk of the other cardiovascular conditions 312 described, which include peripheral vascular disease, aortic stenosis, and ischemic stroke. GRSs 313 calibrated specifically for these conditions will likely improve risk prediction. 314 In summary, genetic factors were shown to significantly modulate the risk of CAD in 315 individuals with elevated lipoprotein(a). Assessment of background polygenic factors may help 316 to personalize risk assessment in individuals with elevated lipoprotein(a) and identify candidates 317 for preventative therapy.

319 ACKNOWLEDGEMENTS

- 320 We acknowledge the participants and individuals involved in the UK Biobank studies; the
- 321 developers of software tools used in this study; and Compute Canada for establishing
- 322 computational resources and providing support.

323 **REFERENCES**

- Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated
 lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331–2339.
- Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk
 factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem
 2005;51:2067–2073.
- Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.
 Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis
 from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention
 Trial Evaluating Rosuvastatin). Circulation 2014;129:635–642.
- Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J.
 Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412–423.
- Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S,
 Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante
 B, Leander K, Faire U de, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M;
 PROCARIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and
 coronary disease. N Engl J Med 2009;361:2518–2528.
- Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene
 accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J
 Clin Invest 1992;90:52–60.
- Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander
 ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common
 diseases identify individuals with risk equivalent to monogenic mutations. Nat Genetics
 2018;50:1219–1224.
- Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N, Larson EA, Edwards T, Shaffer CM, Mosley JD, Maeda S, Horikoshi M, Ritchie M, Williams MS, Larson EB, Crosslin DR, Bland ST, Pacheco JA, Rasmussen-Torvik LJ, Cronkite D, Hripcsak G, Cox NJ, Wilke RA, Stein CM, Rotter JI, Momozawa Y, Roden DM, Krauss RM, Denny JC. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation 2018;138:1839–1849.
- Emdin CA, Khera AV, Natarajan P, Klarin D, Won H-H, Peloso GM, Stitziel NO, Nomura
 A, Zekavat SM, Bick AG, Gupta N, Asselta R, Duga S, Merlini PA, Correa A, Kessler T,
 Wilson JG, Bown MJ, Hall AS, Braund PS, Samani NJ, Schunkert H, Marrugat J, Elosua R,
 McPherson R, Farrall M, Watkins H, Willer C, Abecasis GR, Felix JF, Vasan RS, Lander
 E, Rader DJ, Danesh J, Ardissino D, Gabriel S, Saleheen D, Kathiresan S; CHARGE–Heart
 Failure Consortium; CARDIoGRAM Exome Consortium. Phenotypic characterization of
 genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol 2016;68:2761–2772.

- Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of
 aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477.
- Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and
 increased risk of heart failure in the general population. JACC Heart Fail 2016;4:78–87.
- Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic
 stroke. J Am Coll Cardiol 2019;74:54–66.
- Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F,
 Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH,
 Ishaq M, Rasheed SZ, Memon F-R, Mahmood K, Ahmed N, Frossard P, Tsimikas S,
 Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J. Apolipoprotein(a) isoform size,
 lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation
 analysis. Lancet Diabetes Endocrinol 2017;5:524–533.
- 374 14. Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, Vaarhorst A, Kangas 375 AJ, Lyytikäinen LP, Pirinen M, Pool R, Sarin AP, Soininen P, Tukiainen T, Wang Q, 376 Tiainen M, Tynkkynen T, Amin N, Zeller T, Beekman M, Deelen J, van Dijk KW, Esko T, 377 Hottenga JJ, van Leeuwen EM, Lehtimäki T, Mihailov E, Rose RJ, de Craen AJM, Gieger 378 C, Kähönen M, Perola M, Blankenberg S, Savolainen MJ, Verhoeven A, Viikari J, 379 Willemsen G, Boomsma DI, van Duijn CM, Eriksson J, Jula A, Järvelin MR, Kaprio J, 380 Metspalu A, Raitakari O, Salomaa V, Slagboom PE, Waldenberger M, Ripatti S, Ala-381 Korpela M. Genome-wide study for circulating metabolites identifies 62 loci and reveals 382 novel systemic effects of LPA. Nat Commun 2016;7:11122.
- 15. Coassin S, Erhart G, Weissensteiner H, Eca Guimarães de Araújo M, Lamina C, Schönherr
 S, Forer L, Haun M, Losso JL, Köttgen A, Schmidt K, Utermann G, Peters A, Gieger C,
 Strauch K, Finkenstedt A, Bale R, Zoller H, Paulweber B, Eckardt K-U, Hüttenhofer A,
 Huber LA, Kronenberg F. A novel but frequent variant in LPA KIV-2 is associated with a
 pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J 2017;38:1823–1831.
- 16. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H,
 Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik
 P, Masana L, Reiner Z, Taskinen M-R, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a)
 as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–2853.
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ,
 Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S,
 Guerriero J, Viney NJ, O'Dea L, Witztum JL. Lipoprotein(a) reduction in persons with
 cardiovascular disease. N Engl J Med 2020;382:244–255.
- 18. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes
 SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense
 oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two
 randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016;388:2239–
 2253.

401 19. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang
402 Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting
403 apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet
404 2015;386:1472–1483.

- Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, Boffa M, Koschinsky M,
 Wang X, Yusuf S, INTERHEART Investigators. Lipoprotein(a) levels and the risk of
 myocardial infarction among 7 ethnic groups. Circulation 2019;139:1472–1482.
- 408 21. Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. High
 409 lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective
 410 cohort study. Lancet Diabetes Endocrinol 2016;4:577–587.
- 22. Khera AV, Chaffin M, Zekavat SM, Collins RL, Roselli C, Natarajan P, Lichtman JH.,
 D'Onofrio G, Mattera J, Dreyer R, Spertus JA., Taylor KD, Psaty PM, Rich SS, Post W,
 Gupta N, Gabriel S, Lander E, Ida Chen YD, Talkowski ME, Rotter JI, Krumholz HM,
 Kathiresan S. Whole-genome sequencing to characterize monogenic and polygenic
 contributions in patients hospitalized with early-onset myocardial infarction. Circulation
 2019;139:1593–1602.
- 417 23. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, Genovese G, Loh 418 PR, Bhatia G, Do R, Hayeck T, Won HH; Schizophrenia Working Group of the Psychiatric 419 Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer 420 (DRIVE) study, Kathiresan S, Pato M, Pato C, Tamimi R, Stahl E, Zaitlen N, Pasaniuc B, 421 Belbin G, Kenny EE, Schierup MH, De Jager P, Patsopoulos NA, McCarroll S, Daly M, 422 Purcell S, Chasman D, Neale B, Goddard M, Visscher PM, Kraft P, Patterson N, Price AL. 423 Modeling linkage disequilibrium increases accuracy of polygenic risk scores. Am J Hum 424 Genet 2015;97:576–592.
- 425 24. Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster
 426 V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S. Polygenic risk score
 427 identifies subgroup with higher burden of atherosclerosis and greater relative benefit from
 428 statin therapy in the primary prevention setting. Circulation 2017;135:2091–2101.
- Pereira A, Mendonca MI, Borges S, Sousa AC, Freitas S, Henriques E, Rodrigues M,
 Freitas AI, Guerra G, Freitas C, Pereira D, Brehm A, Reis RPD. Additional value of a
 combined genetic risk score to standard cardiovascular stratification. Genet Mol Biol
 2018;41:766–774.
- 433 26. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
 434 Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie
 435 S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and
 436 genomic data. Nature 2018;562:203–209.
- 437 27. Verbeek R, Boekholdt SM, Stoekenbroek RM, Hovingh GK, Witztum JL, Wareham NJ,
 438 Sandhu MS, Khaw KT, Tsimikas S. Population and assay thresholds for the predictive
 439 value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective
 440 Population Study. J Lipid Res 2016;57:697-705.

- 441 28. Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol
 442 2010;4:240–247.
- 443 29. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young
- 444 R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A,
- 445 Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C,
- 446 Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM,
- 447 Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into
- 448 Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of 449 LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering
- 450 therapies: a Mendelian randomization analysis. JAMA Cardiol 2018;3:619–627.
- 30. Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20%
 in secondary prevention. Arterioscler Thromb Vasc Biol 2020;40:255–266.
- Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial
 hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General
 Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016;37:1384–1394.
- Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto
 JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus
 atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol
 2003;92:152–160.
- 33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P,
 de Bakker PIW, Daly MJ, Sham PC. PLINK: A tool set for whole-genome association and
 population-based linkage analyses. Am J Hum Genet 2007;81:559–575.
- Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon
 A, Morales J, Mountjoy E, Sollis E, Suveges D, Vrousgou O, Whetzel PL, Amode R,
 Guillen JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorff LA,
 Cunningham F, Parkinson H. The NHGRI-EBI GWAS Catalog of published genome-wide
 association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res
 2019;47:D1005–D1012.
- 470 35. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, 471 Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, 472 Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, 473 Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, 474 Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, 475 Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS; CHARGE 476 Extracoronary Calcium Working Group. Genetic associations with valvular calcification 477 and aortic stenosis. N Engl J Med. 2013;368:503-512.
- 478 36. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, Jones GT,
 479 van Rij AM, Eapen DJ, Baas AF, Tregouet DA, Morange PE, Emmerich J, Lindblad B,
 480 Gottsäter A, Kiemeny LA, Lindholt JS, Sakalihasan N, Ferrell RE, Carey DJ, Elmore JR,

481 Tsao PS, Grarup N, Jørgensen T, Witte DR, Hansen T, Pedersen O, Pola R, Gaetani E, 482 Magnadottir HB, Wijmenga C, Tromp G, Ronkainen A, Ruigrok YM, Blankensteijn JD, 483 Mueller T, Wells PS, Corral J, Soria JM, Souto JC, Peden JF, Jalilzadeh S, Mayosi BM, 484 Keavney B, Strawbridge RJ, Sabater-Lleal M, Gertow K, Baldassarre D, Nyyssönen K, 485 Rauramaa R, Smit AJ, Mannarino E, Giral P, Tremoli E, de Faire U, Humphries SE, 486 Hamsten A, Haraldsdottir V, Olafsson I, Magnusson MK, Samani NJ, Levey AI, Markus 487 HS, Kostulas K, Dichgans M, Berger K, Kuhlenbäumer G, Ringelstein EB, Stoll M, 488 Seedorf U, Rothwell PM, Powell JT, Kuivaniemi H, Onundarson PT, Valdimarsson E, 489 Matthiasson SE, Gudbjartsson DF, Thorgeirsson G, Quyyumi AA, Watkins H, Farrall M, 490 Thorsteinsdottir U, Stefansson K.. Apolipoprotein(a) genetic sequence variants associated 491 with systemic atherosclerosis and coronary atherosclerotic burden but not with venous 492 thromboembolism. J Am Coll Cardiol. 2012;60:722-729.

- 493 37. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q, 494 Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, Wang L, 495 Chen J, Saleheen D, Lee JS, Miller DR, Reaven P, Alba PR, Patterson OV, DuVall SL, 496 Boden WE, Beckman JA, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson 497 PWF, O'Donnell CJ, Kathiresan S; VA Million Veteran Program, Tsao PS, Damrauer SM. 498 Genome-wide association study of peripheral artery disease in the Million Veteran 499 Program. Nature Med 2019;25:1274–1279.
- 500 38. Trinder M, Li X, DeCastro ML, Cermakova L, Sadananda S, Jackson LM, Azizi H, 501 Mancini GBJ, Francis GA, Frohlich J, Brunham LR. Risk of premature atherosclerotic 502 disease in patients with monogenic versus polygenic familial hypercholesterolemia. J Am 503 Coll Cardiol. 2019;74:512-522.
- 504 39. Fahed AC, Wang M, Homburger JR, Patel AP, Bick AG, Neben CL, Lai C, Brockman D, 505 Philippakis A, Ellinor PT, Cassa CA, Lebo M, Ng K, Lander ES, Zhou AY, Kathiresan S, 506 Khera AV. Polygenic background modifies penetrance of monogenic variants conferring 507 risk for coronary artery disease, breast cancer, or colorectal cancer. medRxiv 508 2019;19013086.
- 509 40. Oetjens MT, Kelly MA, Sturm AC, Martin CL, Ledbetter DH. Quantifying the polygenic 510 contribution to variable expressivity in eleven rare genetic disorders. Nat Commun 511 2019;10:4897.

512 41. Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, Bjornsson E, Norddahl GL, Jonasdottir A, Jonasdottir A, Eggertsson HP, Gretarsdottir S, 513 514 Thorleifsson G, Indridason OS, Palsson R, Jonasson F, Jonsdottir I, Evjolfsson GI, 515

- Sigurdardottir O, Olafsson I, Danielsen R, Matthiasson SE, Kristmundsdottir S,
- 516 Halldorsson BV, Hreidarsson AB, Valdimarsson EM, Gudnason T, Benediktsson R,
- 517 Steinthorsdottir V, Thorsteinsdottir U, Holm H, Stefansson K. Lipoprotein(a) concentration 518 and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019;74:2982–2994.
- 519 Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit 42. 520 J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with

- 521 lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol
 522 2014;64:851–860.
- 43. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J,
 Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM.
 Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white
 subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation
 2012;125:241–249.
- 44. Gupta R, Vasisht S, Bahl VK, Wasir HS. Correlation of lipoprotein (a) to angiographically
 defined coronary artery disease in Indians. Int J Cardiol 1996;57:265–270.
- 45. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde
 CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O,
 Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical
 benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet
 2015;385:2264–2271.
- 46. Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech
 AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT.
 Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease
 Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. doi:
 10.1161/CIRCULATIONAHA.119.043805.
- 540 47. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM, Dehghan
 541 A, Muller DC, Elliott P, Tzoulaki I. Predictive accuracy of a polygenic risk score–enhanced
 542 prediction model vs a clinical risk score for coronary artery disease. JAMA 2020;323:636–
 543 645.
- 544 48. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE.
 545 Comparison of sociodemographic and health-related characteristics of UK Biobank
 546 participants with those of the general population. Am J Epidemiol 2017;186:1026–1034.

548 FIGURES



549

550 Figure 1. Genomic scores for coronary artery disease associate with traditional

551cardiovascular risk factors. The distribution of coronary artery disease genomic score552percentiles are displayed for traditional cardiovascular risk factors assessed at study enrollment553which include: (A) hypertension, (B) high low-density lipoprotein cholesterol (LDL-C \ge 4.9554mmol/L), (C) diabetes mellitus, (D) obesity (body mass index \ge 30 kg/m²), (E) current smoking555status, and (F) a sum of the aforementioned risk factors. Boxplots display the median and556interquartile range. The boxplot's whiskers show the range and the accompanying density557distribution. *** p<0.001, **** p<0.0001.</td>



560 Figure 2. Elevated lipoprotein(a) is a major determinant of coronary artery disease

561 genomic risk scores. The distribution of coronary artery disease genomic risk score percentiles 562 are displayed across strata of lipoprotein(a) levels calculated (A) with and (B) without genetic 563 variants in proximity to the LPA gene. Boxplots display the median and interquartile range. The 564 boxplot's whiskers show the range and the accompanying density distribution. (C) The 565 standardized effect sizes for the top 100 genetic variants used in calculating coronary artery 566 disease genomic risk scores are shown coloured by reported associations with traditional or 567 emerging cardiovascular risk factors in the NHGRI-EBI Genome-Wide Association Study 568 Catalog. Lipoprotein(a) [Lp(a)].

569





- 576 first 4 components of genetic ancestry and genotyping array/batch. The darker and lighter blue
- 577 shading represent the standard error and 95% confidence interval, respectively.



580 Figure 4. Coronary artery disease genomic risk scores are a modifier of risk of myocardial 581 infarction for individuals with elevated lipoprotein(a). The prevalence of myocardial 582 infarction for each decile of coronary artery disease genomic risk score percentile is shown for 583 scores calculated (A) with and (B) without genetic variants in proximity to the LPA. Solid lines 584 depict linear regression analyses and gray shading indicate the associated 95% confidence 585 interval stratified by non-elevated versus elevated lipoprotein(a) levels. Time-to-first-event 586 analyses are displayed for risk of myocardial infarction events stratified by quintiles of coronary 587 artery disease genomic risk score percentile among individuals with elevated lipoprotein(a) (\geq 588 120 nmol/L) calculated (C) with and (D) without genetic variants in proximity to the LPA gene. 589 The solid black line depicts the risk of myocardial infarction among a reference group comprised 590 of all individuals with non-elevated lipoprotein(a) (Lp(a)-, < 120 nmol/L). The horizontal, dotted 591 black line depicts the myocardial infarction-free probability of the non-elevated lipoprotein(a) 592 reference group at 70 years-of-age.

593 TABLES

594 Table 1. Enrollment characteristics and cardiovascular history of the study group. High-

595 density lipoprotein cholesterol (HDL-C), interquartile range (IQR), low-density lipoprotein

596 cholesterol (LDL-C) standard deviation (SD).

Characteristic	Measurement	Values
n	no.	408896
Age	mean (SD)	56.9 (8.0)
Female sex	no. (%)	221082 (54.1)
Hypertension	no. (%) / n	110888 (27.2) / 408256
Severe hypercholesterolemia	no. (%) / n	31978 (8.2) / 389158
Diabetes mellitus	no. (%) / n	19773 (4.8) / 408003
Obesity	no. (%) / n	98879 (24.3) / 407600
Current smoker	no. (%) / n	41320 (10.1) / 407461
Total cholesterol (mmol/L)	median (IQR) / n	5.8 (1.55) / 389875
LDL-C (mmol/L)	median (IQR) / n	3.61 (1.16) / 389158
Triglycerides (mmol/L)	median (IQR) / n	1.50 (1.11) / 389567
HDL-C (mmol/L)	median (IQR) / n	1.40 (0.50) / 356840
Lipoprotein(a) (nmol/L)	median (IQR) / n	20.1 (50.88) / 310020
Hemoglobin A1c (mmol/mol)	median (IQR) / n	35.2 (5.1) / 389771
C-reactive protein (mg/L)	median (IQR) / n	1.33 (2.1) / 389036